Table 5.
Clinical characteristics of patients with gynecological malignancies having received the COVID-19 vaccine.
| Characteristics | First dose (n = 58) | Second dose (n = 32) |
|---|---|---|
| Age | ||
| Median (IQR) | 62 (53–71.25) | 59.5 (52.75–68) |
| range |
32–83 |
32–82 |
| Type of carcinoma | ||
| Ovarian (%) | 44 (75.9) | 22 (68.8) |
| Endometrium (%) | 3 (5.1) | 3 (9.4) |
| Uterine sarcoma | 1 (1.7) | 1 (3.1) |
| Cervical (%) | 7 (12.2) | 4 (12.5) |
| Vulvar (%) | 1 (1.7) | 0 |
| Dysgerminoma (%) | 1 (1.7) | 1 (3.1) |
| Peritoneal (%) |
1 (1.7) |
1 (3.1) |
| Stage of disease (UICC or FIGO) | ||
| I/II | 7 | 5 |
| III/IV |
51 |
27 |
| Therapy situation | ||
| adjuvant therapy (%) | 18 (31.0) | 9 (28.1) |
| metastatic therapy (%) | 15 (25.9) | 12 (37.5) |
| maintenance therapy (%) | 11 (19.0) | 4 (12.5) |
| recurrent therapy (%) |
14 (24.1) |
7 (21.9) |
| Oncological therapy | ||
| Chemotherapy (%) | 31 (53.4) | 19 (59.4) |
| Targeted therapy (%) | 10 (17.2) | 6 (18.8) |
| Immunotherapy ± chemotherapy (%) | 7 (12.2) | 4 (12.5) |
| none (vaccinated before start of therapy) (%) | 10 (17.2) | 3 (9.4) |